Puma Biotechnology (PBYI)
(Delayed Data from NSDQ)
$3.04 USD
+0.06 (2.01%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $3.04 0.00 (0.00%) 6:30 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
PBYI 3.04 +0.06(2.01%)
Will PBYI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PBYI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PBYI
Puma Biotechnology (PBYI) Falls 38% in 3 Months: Here's Why
Implied Volatility Surging for Puma Biotechnology (PBYI) Stock Options
PBYI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat
Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates
What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings?
Other News for PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Stockholders Elect Leadership and Approve Amendments
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Beyond The Numbers: 4 Analysts Discuss Puma Biotechnology Stock
Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer